BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11677451)

  • 1. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
    Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
    AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver-specific contrast agents for MRI.
    Stark DD; Elizondo G; Fretz CJ
    Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535
    [No Abstract]   [Full Text] [Related]  

  • 5. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
    Fröhlich JM
    J Magn Reson Imaging; 2004 Mar; 19(3):375-6; author reply 376. PubMed ID: 14994308
    [No Abstract]   [Full Text] [Related]  

  • 8. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble-type hepatobiliary contrast agents for MR imaging.
    de Haën C; Gozzini L
    J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
    [No Abstract]   [Full Text] [Related]  

  • 11. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
    Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
    Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status of the clinical development of MR contrast media].
    Laniado M; Kopp AF
    Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
    Reimer P; Schneider G; Schima W
    Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
    Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
    Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal nodular hyperplasia of the liver: serial MRI with Gd-DOTA, superparamagnetic iron oxide, and Gd-EOB-DTPA.
    Kacl GM; Hagspiel KD; Marincek B
    Abdom Imaging; 1997; 22(3):264-7. PubMed ID: 9107647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Focal nodular hyperplasia of the liver: imaging findings with emphasis on the findings of superparamagnetic iron oxide-enhanced MR imaging].
    Han JK; Kim SH
    Korean J Hepatol; 2006 Mar; 12(1):116-9. PubMed ID: 16565614
    [No Abstract]   [Full Text] [Related]  

  • 19. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
    Fowler KJ; Brown JJ; Narra VR
    Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.